Kymera Therapeutics Inc
Отворен
СекторЗдравеопазване
87 1.03
Преглед
Промяна на цената на акция
24 ч
Минимум
83.94
Максимум
87.81
Приходи | 18M -69M |
|---|---|
Продажби | 32M 34M |
EPS | -0.71 |
Марж на печалбата | -201.467 |
Служители | 253 |
EBITDA | 18M -67M |
Препоръки | Силна покупка |
|---|---|
12-месечна прогноза | +37.02% upside |
Следващи печалби | 11.08.2026 г. |
|---|
Пазарна капитализация | -979M 6.1B |
|---|---|
Предишно отваряне | 85.97 |
Предишно затваряне | 87 |
Настроения в новините
By Acuity
50%
50%
146 / 342 Класиране в Healthcare
Kymera Therapeutics Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Относно Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.